MET and breast cancer: As c-Met+ tumor lesions were higher in tumor stage III-IV, in contrast with stage 0, I, and II, we next focused to analyze the relationship between c-Met gene expression and CSC markers in breast cancer subtypes at tumor stage III-IV.